Skip to main content
Erschienen in: Drug Safety 9/2019

01.09.2019 | Systematic Review

Evaluation of Potential Drug–Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis

verfasst von: Mary Grace Fitzmaurice, Adrian Wong, Hannah Akerberg, Simona Avramovska, Pamela L. Smithburger, Mitchell S. Buckley, Sandra L. Kane-Gill

Erschienen in: Drug Safety | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Introduction

There is an increased risk of potential drug–drug interactions (pDDIs) in critically ill patients based on the number of drugs received. The occurrence of pDDIs and clinical significance is not well described.

Objective

The aim was to provide insight into important clinical issues and offer guidance on drug–drug interaction (DDI) surveillance through the performance of a systematic review.

Methods

Five targeted objectives were developed, a priori, which guided study selection and data abstraction. Two independent reviewers extracted the definition, frequency, type, and clinical significance of pDDIs. A meta-analysis was performed to evaluate the proportion of patients exposed to a pDDI. Three data sources (PubMed, Embase, and Scopus) were utilized for the search to include studies that evaluated pDDIs in adult critically ill patients. Included studies in the systematic review and meta-analysis were required to be full text.

Results

A total of 39 studies met inclusion criteria. Definitions of pDDIs were diverse. Frequency of pDDIs varied by study, but was most commonly between one and five pDDIs per patient. Fifty-eight percent of patients were exposed to at least one pDDI during their intensive care unit admission. Types of pDDIs identified were numerous, with aspirin being the most common drug involved. As expected, not all pDDIs were clinically significant. Clinical significance was determined by varied definitions and sources.

Conclusions

Improving the understanding of clinically significant pDDIs and alerts that clinicians encounter may guide better development of surveillance through clinical decision support and decrease alert fatigue.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Uijtendaal EV, van Harssel LL, Hugenholtz GW, Kuck EM, Zwart-van Rijkom JE, Cremer OL, et al. Analysis of potential drug–drug interactions in medical intensive care unit patients. Pharmacotherapy. 2014;34(3):213–9.PubMedCrossRef Uijtendaal EV, van Harssel LL, Hugenholtz GW, Kuck EM, Zwart-van Rijkom JE, Cremer OL, et al. Analysis of potential drug–drug interactions in medical intensive care unit patients. Pharmacotherapy. 2014;34(3):213–9.PubMedCrossRef
2.
Zurück zum Zitat Kannan B, Nagella AB, Sathia Prabhu A, Sasidharan GM, Ramesh AS, Madhugiri V, et al. Incidence of potential drug–drug interactions in a limited and stereotyped prescription setting—comparison of two free online pharmacopoeias. Cureus. 2016;8(11):e886.PubMedPubMedCentral Kannan B, Nagella AB, Sathia Prabhu A, Sasidharan GM, Ramesh AS, Madhugiri V, et al. Incidence of potential drug–drug interactions in a limited and stereotyped prescription setting—comparison of two free online pharmacopoeias. Cureus. 2016;8(11):e886.PubMedPubMedCentral
3.
Zurück zum Zitat Wong A, Wright A, Seger DL, Amato MG, Fiskio JM, Bates D. Comparison of overridden medication-related clinical decision support in the intensive care unit between a commercial system and a legacy system. Appl Clin Inform. 2017;8(3):866–79.PubMedPubMedCentralCrossRef Wong A, Wright A, Seger DL, Amato MG, Fiskio JM, Bates D. Comparison of overridden medication-related clinical decision support in the intensive care unit between a commercial system and a legacy system. Appl Clin Inform. 2017;8(3):866–79.PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Nanji KC, Seger DL, Slight SP, Amato MG, Beeler PE, Her QL, et al. Medication-related clinical decision support alert overrides in inpatients. J Am Med Inform Assoc. 2018;25(5):476–81.PubMedCrossRef Nanji KC, Seger DL, Slight SP, Amato MG, Beeler PE, Her QL, et al. Medication-related clinical decision support alert overrides in inpatients. J Am Med Inform Assoc. 2018;25(5):476–81.PubMedCrossRef
5.
Zurück zum Zitat Kane-Gill SL, O’Connor MF, Rothschild JM, Selby NM, McLean B, Bonafide CP, et al. Technologic distractions (part 1): summary of approaches to manage alert quantity with intent to reduce alert fatigue and suggestions for alert fatigue metrics. Crit Care Med. 2017;45(9):1481–8.PubMedCrossRef Kane-Gill SL, O’Connor MF, Rothschild JM, Selby NM, McLean B, Bonafide CP, et al. Technologic distractions (part 1): summary of approaches to manage alert quantity with intent to reduce alert fatigue and suggestions for alert fatigue metrics. Crit Care Med. 2017;45(9):1481–8.PubMedCrossRef
6.
Zurück zum Zitat Kane-Gill SL, Kirisci L, Verrico MM, Rothschild JM. Analysis of risk factors for adverse drug events in critically ill patients. Crit Care Med. 2012;40(3):823–8.PubMedPubMedCentralCrossRef Kane-Gill SL, Kirisci L, Verrico MM, Rothschild JM. Analysis of risk factors for adverse drug events in critically ill patients. Crit Care Med. 2012;40(3):823–8.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Evans RS, Lloyd JF, Stoddard GJ, Nebeker JR, Samore MH. Risk factors for adverse drug events: a 10-year analysis. Ann Pharmacother. 2005;39(7–8):1161–8.PubMedCrossRef Evans RS, Lloyd JF, Stoddard GJ, Nebeker JR, Samore MH. Risk factors for adverse drug events: a 10-year analysis. Ann Pharmacother. 2005;39(7–8):1161–8.PubMedCrossRef
8.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.PubMedCrossRef Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.PubMedCrossRef
9.
Zurück zum Zitat Monaghan MS, Falls L, Olsen KM. Potential drug interactions with H2-receptor antagonists in intensive care unit patients. Hosp Pharm. 1993;28(4):296–7 (300-1, 5 passim).PubMed Monaghan MS, Falls L, Olsen KM. Potential drug interactions with H2-receptor antagonists in intensive care unit patients. Hosp Pharm. 1993;28(4):296–7 (300-1, 5 passim).PubMed
12.
Zurück zum Zitat Hasan SS, Lim KN, Anwar M, Sathvik BS, Ahmadi K, Yuan AW, et al. Impact of pharmacists’ intervention on identification and management of drug–drug interactions in an intensive care setting. Singap Med J. 2012;53(8):526–31. Hasan SS, Lim KN, Anwar M, Sathvik BS, Ahmadi K, Yuan AW, et al. Impact of pharmacists’ intervention on identification and management of drug–drug interactions in an intensive care setting. Singap Med J. 2012;53(8):526–31.
13.
Zurück zum Zitat Smithburger PL, Kane-Gill SL, Seybert AL. Drug–drug interactions in cardiac and cardiothoracic intensive care units: an analysis of patients in an academic medical centre in the US. Drug Saf. 2010;33(10):879–88.PubMedCrossRef Smithburger PL, Kane-Gill SL, Seybert AL. Drug–drug interactions in cardiac and cardiothoracic intensive care units: an analysis of patients in an academic medical centre in the US. Drug Saf. 2010;33(10):879–88.PubMedCrossRef
14.
Zurück zum Zitat Armahizer MJ, Kane-Gill SL, Smithburger PL, Anthes AM, Seybert AL. Comparing drug–drug interaction severity ratings between bedside clinicians and proprietary databases. ISRN Crit Care. 2013;2013:347346.CrossRef Armahizer MJ, Kane-Gill SL, Smithburger PL, Anthes AM, Seybert AL. Comparing drug–drug interaction severity ratings between bedside clinicians and proprietary databases. ISRN Crit Care. 2013;2013:347346.CrossRef
15.
Zurück zum Zitat Jain S, Jain P, Sharma K, Saraswat P. A prospective analysis of drug interactions in patients of intensive cardiac care unit. J Clin Diagn Res. 2017;11(3):Fc01–fc04.PubMedPubMedCentral Jain S, Jain P, Sharma K, Saraswat P. A prospective analysis of drug interactions in patients of intensive cardiac care unit. J Clin Diagn Res. 2017;11(3):Fc01–fc04.PubMedPubMedCentral
16.
Zurück zum Zitat Depont F, Vargas F, Dutronc H, Giauque E, Ragnaud JM, Galperine T, et al. Drug–drug interactions with systemic antifungals in clinical practice. Pharmacoepidemiol Drug Saf. 2007;16(11):1227–33.PubMedCrossRef Depont F, Vargas F, Dutronc H, Giauque E, Ragnaud JM, Galperine T, et al. Drug–drug interactions with systemic antifungals in clinical practice. Pharmacoepidemiol Drug Saf. 2007;16(11):1227–33.PubMedCrossRef
17.
Zurück zum Zitat Polidori P, Di Giorgio C, Provenzani A. Incidence of potential drug interactions in a transplant centre setting and relevance of electronic alerts for clinical practice support. Inform Prim Care. 2012;20(4):257–62.PubMed Polidori P, Di Giorgio C, Provenzani A. Incidence of potential drug interactions in a transplant centre setting and relevance of electronic alerts for clinical practice support. Inform Prim Care. 2012;20(4):257–62.PubMed
18.
Zurück zum Zitat Ramos GV, Guaraldo L, Japiassu AM, Bozza FA. Comparison of two databases to detect potential drug–drug interactions between prescriptions of HIV/AIDS patients in critical care. J Clin Pharm Ther. 2015;40(1):63–7.PubMedCrossRef Ramos GV, Guaraldo L, Japiassu AM, Bozza FA. Comparison of two databases to detect potential drug–drug interactions between prescriptions of HIV/AIDS patients in critical care. J Clin Pharm Ther. 2015;40(1):63–7.PubMedCrossRef
19.
Zurück zum Zitat Armahizer MJ, Seybert AL, Smithburger PL, Kane-Gill SL. Drug–drug interactions contributing to QT prolongation in cardiac intensive care units. J Crit Care. 2013;28(3):243–9.PubMedCrossRef Armahizer MJ, Seybert AL, Smithburger PL, Kane-Gill SL. Drug–drug interactions contributing to QT prolongation in cardiac intensive care units. J Crit Care. 2013;28(3):243–9.PubMedCrossRef
20.
Zurück zum Zitat Rafiei H, Abdar ME, Amiri M, Ahmadinejad M. The study of harmful and beneficial drug interactions in intensive care, Kerman, Iran. J Intensive Care Med. 2013;14(2):155–8. Rafiei H, Abdar ME, Amiri M, Ahmadinejad M. The study of harmful and beneficial drug interactions in intensive care, Kerman, Iran. J Intensive Care Med. 2013;14(2):155–8.
21.
Zurück zum Zitat Baniasadi S, Farzanegan B, Alehashem M. Important drug classes associated with potential drug–drug interactions in critically ill patients: highlights for cardiothoracic intensivists. Ann Intensive Care. 2015;5(1):44.PubMedPubMedCentralCrossRef Baniasadi S, Farzanegan B, Alehashem M. Important drug classes associated with potential drug–drug interactions in critically ill patients: highlights for cardiothoracic intensivists. Ann Intensive Care. 2015;5(1):44.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Rivkin A, Yin H. Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug–drug interactions in medical intensive care patients. J Crit Care. 2011;26(1):104.e1–6.CrossRef Rivkin A, Yin H. Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug–drug interactions in medical intensive care patients. J Crit Care. 2011;26(1):104.e1–6.CrossRef
23.
Zurück zum Zitat Jankovic SM, Pejcic AV, Milosavljevic MN, Opancina VD, Pesic NV, Nedeljkovic TT, et al. Risk factors for potential drug–drug interactions in intensive care unit patients. J Crit Care. 2018;43:1–6.PubMedCrossRef Jankovic SM, Pejcic AV, Milosavljevic MN, Opancina VD, Pesic NV, Nedeljkovic TT, et al. Risk factors for potential drug–drug interactions in intensive care unit patients. J Crit Care. 2018;43:1–6.PubMedCrossRef
24.
Zurück zum Zitat Bertsche T, Pfaff J, Schiller P, Kaltschmidt J, Pruszydlo MG, Stremmel W, et al. Prevention of adverse drug reactions in intensive care patients by personal intervention based on an electronic clinical decision support system. Intensive Care Med. 2010;36(4):665–72.PubMedCrossRef Bertsche T, Pfaff J, Schiller P, Kaltschmidt J, Pruszydlo MG, Stremmel W, et al. Prevention of adverse drug reactions in intensive care patients by personal intervention based on an electronic clinical decision support system. Intensive Care Med. 2010;36(4):665–72.PubMedCrossRef
25.
Zurück zum Zitat Reis AM, Cassiani SH. Adverse drug events in an intensive care unit of a university hospital. Eur J Clin Pharmacol. 2011;67(6):625–32.PubMedCrossRef Reis AM, Cassiani SH. Adverse drug events in an intensive care unit of a university hospital. Eur J Clin Pharmacol. 2011;67(6):625–32.PubMedCrossRef
26.
Zurück zum Zitat Ahn EK, Kam HJ, Park DK, Jung EY, Lee Y, Park RW. Differences among admitting departments in alerts and alert overrides for drug–drug interaction. Pharmacoepidemiol Drug Saf. 2014;23(4):390–7.PubMedCrossRef Ahn EK, Kam HJ, Park DK, Jung EY, Lee Y, Park RW. Differences among admitting departments in alerts and alert overrides for drug–drug interaction. Pharmacoepidemiol Drug Saf. 2014;23(4):390–7.PubMedCrossRef
27.
Zurück zum Zitat Rodrigues AT, Stahlschmidt R, Granja S, Pilger D, Falcão ALE, Mazzola PG. Prevalence of potential drug–drug interactions in the intensive care unit of a Brazilian teaching hospital. Braz J Pharm Sci. 2017;53(1). Rodrigues AT, Stahlschmidt R, Granja S, Pilger D, Falcão ALE, Mazzola PG. Prevalence of potential drug–drug interactions in the intensive care unit of a Brazilian teaching hospital. Braz J Pharm Sci. 2017;53(1).
28.
Zurück zum Zitat Askari M, Eslami S, Louws M, Dongelmans D, Wierenga P, Kuiper R, et al. Relevance of drug–drug interaction in the ICU—perceptions of intensivists and pharmacists. Stud Health Technol Inform. 2012;180:716–20.PubMed Askari M, Eslami S, Louws M, Dongelmans D, Wierenga P, Kuiper R, et al. Relevance of drug–drug interaction in the ICU—perceptions of intensivists and pharmacists. Stud Health Technol Inform. 2012;180:716–20.PubMed
29.
Zurück zum Zitat Reis AM, Cassiani SH. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics (Sao Paulo, Brazil). 2011;66(1):9–15.PubMedCentralCrossRef Reis AM, Cassiani SH. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics (Sao Paulo, Brazil). 2011;66(1):9–15.PubMedCentralCrossRef
30.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.PubMedCrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.PubMedCrossRef
31.
32.
Zurück zum Zitat Smithburger PL, Kane-Gill SL, Seybert AL. Drug–drug interactions in the medical intensive care unit: an assessment of frequency, severity and the medications involved. Int J Pharm Pract. 2012;20(6):402–8.PubMedCrossRef Smithburger PL, Kane-Gill SL, Seybert AL. Drug–drug interactions in the medical intensive care unit: an assessment of frequency, severity and the medications involved. Int J Pharm Pract. 2012;20(6):402–8.PubMedCrossRef
33.
Zurück zum Zitat Ray S, Pramanik J, Bhattacharyya M, Todi S. Prospective observational evaluation of incidences and implications of drug–drug interactions induced adverse drug reactions in critically ill patients. Indian J Pharm Sci. 2010;72(6):787–92.PubMedPubMedCentralCrossRef Ray S, Pramanik J, Bhattacharyya M, Todi S. Prospective observational evaluation of incidences and implications of drug–drug interactions induced adverse drug reactions in critically ill patients. Indian J Pharm Sci. 2010;72(6):787–92.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Vanham D, Spinewine A, Hantson P, Wittebole X, Wouters D, Sneyers B. Drug–drug interactions in the intensive care unit: do they really matter? J Crit Care. 2017;38:97–103.PubMedCrossRef Vanham D, Spinewine A, Hantson P, Wittebole X, Wouters D, Sneyers B. Drug–drug interactions in the intensive care unit: do they really matter? J Crit Care. 2017;38:97–103.PubMedCrossRef
35.
Zurück zum Zitat Rodrigues AT, Stahlschmidt R, Granja S, Falcao AL, Moriel P, Mazzola PG. Clinical relevancy and risks of potential drug–drug interactions in intensive therapy. Saudi Pharm J. 2015;23(4):366–70.PubMedCrossRef Rodrigues AT, Stahlschmidt R, Granja S, Falcao AL, Moriel P, Mazzola PG. Clinical relevancy and risks of potential drug–drug interactions in intensive therapy. Saudi Pharm J. 2015;23(4):366–70.PubMedCrossRef
36.
Zurück zum Zitat Abideen S. Assessment of prevalence of potential drug–drug interactions in medical intensive care unit of a tertiary care hospital in India. Asian J Pharm Clin Res. 2015;8(1):125–30. Abideen S. Assessment of prevalence of potential drug–drug interactions in medical intensive care unit of a tertiary care hospital in India. Asian J Pharm Clin Res. 2015;8(1):125–30.
37.
Zurück zum Zitat Gulcebi Idriz Oglu M, Kucukibrahimoglu E, Karaalp A, Sarikaya O, Demirkapu M, Onat F, et al. Potential drug–drug interactions in a medical intensive care unit of a university hospital. Turk J Med Sci. 2016;46(3):812–9.PubMedCrossRef Gulcebi Idriz Oglu M, Kucukibrahimoglu E, Karaalp A, Sarikaya O, Demirkapu M, Onat F, et al. Potential drug–drug interactions in a medical intensive care unit of a university hospital. Turk J Med Sci. 2016;46(3):812–9.PubMedCrossRef
38.
Zurück zum Zitat Askari M, Eslami S, Louws M, Wierenga PC, Dongelmans DA, Kuiper RA, et al. Frequency and nature of drug–drug interactions in the intensive care unit. Pharmacoepidemiol Drug Saf. 2013;22(4):430–7.PubMedCrossRef Askari M, Eslami S, Louws M, Wierenga PC, Dongelmans DA, Kuiper RA, et al. Frequency and nature of drug–drug interactions in the intensive care unit. Pharmacoepidemiol Drug Saf. 2013;22(4):430–7.PubMedCrossRef
39.
Zurück zum Zitat Moura C, Prado N, Acurcio F. Potential drug–drug interactions associated with prolonged stays in the intensive care unit: a retrospective cohort study. Clin Drug Investig. 2011;31(5):309–16.PubMedCrossRef Moura C, Prado N, Acurcio F. Potential drug–drug interactions associated with prolonged stays in the intensive care unit: a retrospective cohort study. Clin Drug Investig. 2011;31(5):309–16.PubMedCrossRef
40.
Zurück zum Zitat Mahmoud Abd El Samia Mohamed, Gad Z, El-Nimr N, Abdel Razek A. Prevalence and pattern of potential drug–drug interactions in the critical care units of a tertiary hospital in Alexandria, Egypt. Adv Pharmacoepidemiol Drug Saf. 2013;2:144. Mahmoud Abd El Samia Mohamed, Gad Z, El-Nimr N, Abdel Razek A. Prevalence and pattern of potential drug–drug interactions in the critical care units of a tertiary hospital in Alexandria, Egypt. Adv Pharmacoepidemiol Drug Saf. 2013;2:144.
41.
Zurück zum Zitat Hamidy MY, Fauzia D. Significant drug interactions among intensive care unit patients. Asian J Pharm Clin Res. 2017;10(14):35–8.CrossRef Hamidy MY, Fauzia D. Significant drug interactions among intensive care unit patients. Asian J Pharm Clin Res. 2017;10(14):35–8.CrossRef
42.
Zurück zum Zitat Bista D, Saha A, Mishra P, Palaian S, Shankar PR. Pattern of potential drug–drug interactions in the intensive care unit of a teaching hospital in Nepal: a pilot study. J Clin Diagn. 2009;3:1713–6. Bista D, Saha A, Mishra P, Palaian S, Shankar PR. Pattern of potential drug–drug interactions in the intensive care unit of a teaching hospital in Nepal: a pilot study. J Clin Diagn. 2009;3:1713–6.
43.
Zurück zum Zitat Carvalho REFLD, Reis AMM, Faria LMPD, Zago KSDA, Cassiani SHDB. Prevalence of drug interactions in intensive care units in Brazil. Acta Paul Enferm. 2013;26(2):150–7.CrossRef Carvalho REFLD, Reis AMM, Faria LMPD, Zago KSDA, Cassiani SHDB. Prevalence of drug interactions in intensive care units in Brazil. Acta Paul Enferm. 2013;26(2):150–7.CrossRef
44.
Zurück zum Zitat Alvim MM, Silva LA, Leite IC, Silverio MS. Adverse events caused by potential drug–drug interactions in an intensive care unit of a teaching hospital. Rev Bras Ter Intensiva. 2015;27(4):353–9.PubMedPubMedCentralCrossRef Alvim MM, Silva LA, Leite IC, Silverio MS. Adverse events caused by potential drug–drug interactions in an intensive care unit of a teaching hospital. Rev Bras Ter Intensiva. 2015;27(4):353–9.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Amkreutz J, Koch A, Buendgens L, Muehlfeld A, Trautwein C, Eisert A. Prevalence and nature of potential drug–drug interactions among kidney transplant patients in a German intensive care unit. Int J Clin Pharm. 2017;39(5):1128–39.PubMedCrossRef Amkreutz J, Koch A, Buendgens L, Muehlfeld A, Trautwein C, Eisert A. Prevalence and nature of potential drug–drug interactions among kidney transplant patients in a German intensive care unit. Int J Clin Pharm. 2017;39(5):1128–39.PubMedCrossRef
46.
Zurück zum Zitat Łój P, Olender A, Slezak W, Krzych LJ. Pharmacokinetic drug–drug interactions in the intensive care unit—single-centre experience and literature review. Anaesthesiol Intensive Ther. 2017;49(4):259–67.PubMed Łój P, Olender A, Slezak W, Krzych LJ. Pharmacokinetic drug–drug interactions in the intensive care unit—single-centre experience and literature review. Anaesthesiol Intensive Ther. 2017;49(4):259–67.PubMed
47.
Zurück zum Zitat Farzanegan B, Alehashem M, Bastani M, Baniasadi S. Potential drug–drug interactions in cardiothoracic intensive care unit of a pulmonary teaching hospital. J Clin Pharmacol. 2015;55(2):132–6.PubMedCrossRef Farzanegan B, Alehashem M, Bastani M, Baniasadi S. Potential drug–drug interactions in cardiothoracic intensive care unit of a pulmonary teaching hospital. J Clin Pharmacol. 2015;55(2):132–6.PubMedCrossRef
48.
Zurück zum Zitat Gupta M, Chincholkar AS, Wagh RJ, Maheshwari N, Siddiqui W. A study of potential drug–drug interactions among critically ill patients at a tertiary care hospital. Int J Basic Clin Pharmacol. 2016;5(4):1281–5.CrossRef Gupta M, Chincholkar AS, Wagh RJ, Maheshwari N, Siddiqui W. A study of potential drug–drug interactions among critically ill patients at a tertiary care hospital. Int J Basic Clin Pharmacol. 2016;5(4):1281–5.CrossRef
49.
Zurück zum Zitat Joshua L, Devi P, Guido S. Adverse drug reactions in medical intensive care unit of a tertiary care hospital. Pharmacoepidemiol Drug Saf. 2009;18(7):639–45.PubMedCrossRef Joshua L, Devi P, Guido S. Adverse drug reactions in medical intensive care unit of a tertiary care hospital. Pharmacoepidemiol Drug Saf. 2009;18(7):639–45.PubMedCrossRef
50.
Zurück zum Zitat Lima RE, De Bortoli Cassiani SH. Potential drug interactions in intensive care patients at a teaching hospital. Rev Lat Am Enfermagem. 2009;17(2):222–7.PubMedCrossRef Lima RE, De Bortoli Cassiani SH. Potential drug interactions in intensive care patients at a teaching hospital. Rev Lat Am Enfermagem. 2009;17(2):222–7.PubMedCrossRef
51.
Zurück zum Zitat Ko Y, Malone DC, Skrepnek GH, Armstrong EP, Murphy JE, Abarca J, et al. Prescribers’ knowledge of and sources of information for potential drug–drug interactions: a postal survey of US prescribers. Drug Saf. 2008;31(6):525–36.PubMedCrossRef Ko Y, Malone DC, Skrepnek GH, Armstrong EP, Murphy JE, Abarca J, et al. Prescribers’ knowledge of and sources of information for potential drug–drug interactions: a postal survey of US prescribers. Drug Saf. 2008;31(6):525–36.PubMedCrossRef
52.
Zurück zum Zitat Shakeel F, Khan JA, Aamir M. Relationship of factors affecting clinically important drug interactions and their significance in surgical intensive care units in Pakistan. Lat Am J Pharm. 2018;37(4):643–50. Shakeel F, Khan JA, Aamir M. Relationship of factors affecting clinically important drug interactions and their significance in surgical intensive care units in Pakistan. Lat Am J Pharm. 2018;37(4):643–50.
53.
Zurück zum Zitat Zheng WY, Richardson LC, Li L, Day RO, Westbrook JI, Baysari MT. Drug–drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2018;74(1):15–27.PubMedCrossRef Zheng WY, Richardson LC, Li L, Day RO, Westbrook JI, Baysari MT. Drug–drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2018;74(1):15–27.PubMedCrossRef
54.
Zurück zum Zitat Wang LM, Wong M, Lightwood JM, Cheng CM. Black box warning contraindicated comedications: concordance among three major drug interaction screening programs. Ann Pharmacother. 2010;44(1):28–34.PubMedCrossRef Wang LM, Wong M, Lightwood JM, Cheng CM. Black box warning contraindicated comedications: concordance among three major drug interaction screening programs. Ann Pharmacother. 2010;44(1):28–34.PubMedCrossRef
55.
Zurück zum Zitat Scheife RT, Hines LE, Boyce RD, Chung SP, Momper JD, Sommer CD, et al. Consensus recommendations for systematic evaluation of drug–drug interaction evidence for clinical decision support. Drug Saf. 2015;38(2):197–206.PubMedPubMedCentralCrossRef Scheife RT, Hines LE, Boyce RD, Chung SP, Momper JD, Sommer CD, et al. Consensus recommendations for systematic evaluation of drug–drug interaction evidence for clinical decision support. Drug Saf. 2015;38(2):197–206.PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Ayvaz S, Horn J, Hassanzadeh O, Zhu Q, Stan J, Tatonetti NP, et al. Toward a complete dataset of drug–drug interaction information from publicly available sources. J Biomed Inform. 2015;55:206–17.PubMedPubMedCentralCrossRef Ayvaz S, Horn J, Hassanzadeh O, Zhu Q, Stan J, Tatonetti NP, et al. Toward a complete dataset of drug–drug interaction information from publicly available sources. J Biomed Inform. 2015;55:206–17.PubMedPubMedCentralCrossRef
57.
Zurück zum Zitat Tilson H, Hines LE, McEvoy G, Weinstein DM, Hansten PD, Matuszewski K, et al. Recommendations for selecting drug–drug interactions for clinical decision support. Am J Health System Pharm. 2016;73(8):576–85.CrossRef Tilson H, Hines LE, McEvoy G, Weinstein DM, Hansten PD, Matuszewski K, et al. Recommendations for selecting drug–drug interactions for clinical decision support. Am J Health System Pharm. 2016;73(8):576–85.CrossRef
60.
Zurück zum Zitat Stockley’s drug interactions: a source book of interactions, their mechanisms, clinical importance and management. London; Chicago: Pharmaceutical Press, 2006. Print. Stockley’s drug interactions: a source book of interactions, their mechanisms, clinical importance and management. London; Chicago: Pharmaceutical Press, 2006. Print.
62.
Zurück zum Zitat McEvoy DS, Sittig DF, Hickman TT, Aaron S, Ai A, Amato M, et al. Variation in high-priority drug–drug interaction alerts across institutions and electronic health records. J Am Med Inform Assoc. 2017;24(2):331–8.PubMedCrossRef McEvoy DS, Sittig DF, Hickman TT, Aaron S, Ai A, Amato M, et al. Variation in high-priority drug–drug interaction alerts across institutions and electronic health records. J Am Med Inform Assoc. 2017;24(2):331–8.PubMedCrossRef
63.
Zurück zum Zitat Cornu P, Phansalkar S, Seger DL, Cho I, Pontefract S, Robertson A, et al. High-priority and low-priority drug–drug interactions in different international electronic health record systems: a comparative study. Int J Med Inform. 2018;111:165–71.PubMedCrossRef Cornu P, Phansalkar S, Seger DL, Cho I, Pontefract S, Robertson A, et al. High-priority and low-priority drug–drug interactions in different international electronic health record systems: a comparative study. Int J Med Inform. 2018;111:165–71.PubMedCrossRef
64.
Zurück zum Zitat van Roon EN, Flikweert S, le Comte M, Langendijk PN, Kwee-Zuiderwijk WJ, Smits P, et al. Clinical relevance of drug–drug interactions: a structured assessment procedure. Drug Saf. 2005;28(12):1131–9.PubMedCrossRef van Roon EN, Flikweert S, le Comte M, Langendijk PN, Kwee-Zuiderwijk WJ, Smits P, et al. Clinical relevance of drug–drug interactions: a structured assessment procedure. Drug Saf. 2005;28(12):1131–9.PubMedCrossRef
65.
Zurück zum Zitat Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8(1):2–10.PubMedCrossRef Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8(1):2–10.PubMedCrossRef
Metadaten
Titel
Evaluation of Potential Drug–Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis
verfasst von
Mary Grace Fitzmaurice
Adrian Wong
Hannah Akerberg
Simona Avramovska
Pamela L. Smithburger
Mitchell S. Buckley
Sandra L. Kane-Gill
Publikationsdatum
01.09.2019
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 9/2019
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-019-00829-y

Weitere Artikel der Ausgabe 9/2019

Drug Safety 9/2019 Zur Ausgabe